Why Cancer?-Reference-Cited by-同舟云学术

Why Cancer?

Published:2016-05-18 Issue:7 Volume:34 Page:625-627
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Haycox Alan

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-016-0413-0.pdf

Reference5 articles.

1. McCabe C, Paul A, Fell G, Paulden M. Cancer drugs fund 2.0: a missed opportunity? Pharmacoeconomics. Epub 22 March 2016.

2. Haycox A. How much should the NHS pay for a QALY? Pharmacoconomics. 2013;31:357–9.

3. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the NICE cost effectiveness threshold. CHE Research Paper 81. York: University of York, Centre for Health Economics; 2013.

4. Towse A. Should NICE’s threshold range for cost per QALY be raised? Yes. BMJ. 2009;338:b181.

5. Rafferty J. Should NICE’s threshold range for cost per QALY be raised? No. BMJ. 2009;338:b185.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations;BMJ Open;2023-10

2. Introduction of managed entry agreements in Korea: Problem, policy, and politics;Frontiers in Pharmacology;2023-04-13

3. The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach;Expert Review of Pharmacoeconomics & Outcomes Research;2023-03-07

4. Editorial: Pharmaceutical policy, impact and health outcomes;Frontiers in Pharmacology;2023-02-14

5. Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis;Frontiers in Pharmacology;2022-08-22